Corbus Pharmaceuticals Presents Pre-Clinical Characterization Of Nectin-4 ADC CRB-701
Portfolio Pulse from Benzinga Newsdesk
Corbus Pharmaceuticals has presented pre-clinical characterization of Nectin-4 ADC CRB-701, demonstrating a differentiated nonclinical profile relative to enfortumab vedotin. Early dose escalation clinical data supports these differentiating features. The company is on schedule to initiate its US study in Q1-2024.
October 16, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corbus Pharmaceuticals' pre-clinical data for Nectin-4 ADC CRB-701 shows promising differentiation from enfortumab vedotin. The company is set to begin its US study in Q1-2024.
The news is directly related to Corbus Pharmaceuticals and its product Nectin-4 ADC CRB-701. The positive pre-clinical data and the upcoming US study could potentially boost investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100